Zai Lab Limited
Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.
ZLAB Nasdaq
ISIN KYG9887T1168 SEC CIK 1704292 LEI 549300P2UYQ9U5LY1T58
Follow Zai Lab
Weekly email: filings, results
Revenue, last quarter
$107.6M
−6.7% vs same quarter last year
Net income
−$46.1M
−28.3% vs same quarter last year
EPS, diluted
−$0.04
−33.3% vs same quarter last year
Operating cash flow
−$57.9M
−80.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $457.2M | −$175.5M |
| FY24 | $397.6M | −$257.1M |
| FY23 | $266.7M | −$334.6M |
| FY22 | $212.7M | −$443.3M |
| FY21 | $144.1M | −$704.5M |
| FY20 | $49M | −$268.9M |
| FY19 | $13M | −$195.1M |
| FY18 | $129K | −$139.1M |
| FY17 | - | −$50.4M |
| FY16 | - | −$37.5M |
| FY15 | - | −$18M |
| FY14 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 58.3% | −50.2% | −38.4% |
| FY24 | 63% | −71% | −64.7% |
| FY23 | 64.1% | −137.4% | −125.5% |
| FY22 | 65.2% | −190.1% | −208.4% |
| FY21 | 63.7% | −485.8% | −488.9% |
| FY20 | 65.8% | −616.4% | −549.3% |
| FY19 | 71.1% | −1564.9% | −1502.3% |
| FY18 | 66.6% | −109897.7% | −107810.1% |
| FY17 | - | - | - |
| FY16 | - | - | - |
| FY15 | - | - | - |
| FY14 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$158.9M |
| FY24 | −$220.5M |
| FY23 | −$205.4M |
| FY22 | −$392.2M |
| FY21 | −$567.5M |
| FY20 | −$226.2M |
| FY19 | −$197M |
| FY18 | −$107.6M |
| FY17 | −$41.5M |
| FY16 | −$34.4M |
| FY15 | −$12.2M |
| FY14 | - |
- Zai Lab
- Healthcare median
Show the numbers
| Year | Zai Lab | Healthcare median |
|---|---|---|
| FY25 | −38.4% | −30.6% |
| FY24 | −64.7% | −47% |
| FY23 | −125.5% | −58% |
| FY22 | −208.4% | −80.4% |
| FY21 | −488.9% | −71.9% |
| FY20 | −549.3% | −62.2% |
| FY19 | −1502.3% | −46.3% |
| FY18 | −107810.1% | −49.6% |
| FY17 | - | −45.9% |
| FY16 | - | −36% |
| FY15 | - | −38.4% |
| FY14 | - | −35.5% |